Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics
Background: Patients with schizophrenia are at high risk of pre-mature mortality due to cardiovascular disease (CVD). Our group has completed studies in pharmacogenomics and metabolomics that have independently identified perturbations in one-carbon metabolism as associated with risk factors for CVD...
Main Authors: | Kristen M. Ward, Kyle Burghardt, A. Zarina Kraal, Andrew Jaeger, Larisa Yeomans, Cora McHugh, Alla Karnovsky, Kathleen A. Stringer, Vicki L. Ellingrod |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.623143/full |
Similar Items
-
Dietary Glutamic Acid, Obesity, and Depressive Symptoms in Patients With Schizophrenia
by: Pooja Kumar, et al.
Published: (2021-01-01) -
Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics
by: Christopher Blazy, et al.
Published: (2022-06-01) -
Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments
by: Marta Hernandez, et al.
Published: (2024-02-01) -
Atypical Antipsychotics and the Human Skeletal Muscle Lipidome
by: Kyle J. Burghardt, et al.
Published: (2018-10-01) -
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
by: Nana Li, et al.
Published: (2020-02-01)